CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations Development and validation of a simple risk score to predict 30-day readmission after percutaneous coronary intervention in a cohort of medicare patients Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry：The EuroCTO (CASTLE) Score Cardiovascular Biomarkers and Imaging in Older Adults: JACC Council Perspectives Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials Long-Term Outcomes of Biodegradable Versus Second-Generation Durable Polymer Drug-Eluting Stent Implantations for Myocardial Infarction Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials
|<<... 8 9 10 11 12 13 14 ...>>|

Guideline2014 Jul 1;63(25 Pt B):2889-934.

JOURNAL：J Am Coll Cardiol. Article Link

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone NJ, Robinson JG, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Keywords: ACC/AHA Practice Guideline; biomarkers, pharmacological; cardiovascular disease; cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction behavior; secondary prevention

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top